Company Overview
For personal use only
Our mission in action
01
World leaders
Incannex Healthcare
(NASDAQ: IXHL, ASX: IHL)
is a world leader in the
development of novel
cannabinoid pharmaceuticals
and psychedelic therapies.
Incannex
02
Diversified portfolio
Diversified portfolio
of candidates:
clinical and pre-clinical
studies have established
proof of concept over 28 drug
candidates for a broad range
of under-met medical conditions
representing major economic
opportunities. Incannex is not
a "one trick pony".
03
Backed by patents
Pharmaceuticals
backed by patents:
recently completed acquisition
strategically expands
intellectual property portfolio;
Incannex owns 19 patents and
27 provisional applications.
Granted patents offer 20 years
of commercial exclusivity.
(04
Purposefully distinct
Purposefully distinct from
other medicinal cannabis
companies:
combination cannabinoid
drugs (CBD or THC combined
with existing expired-patent
pharmaceutical compounds)
observed to have superior
therapeutic outcomes
to cannabinoids and the
partner compound alone
in sleep apnoea, traumatic
brain injuries and various
inflammatory conditions.
05
Commercial focus
Focus on commercialisation:
project ideation is completed,
and we are now working
towards FDA and EMA
development programs for
drug registration and marketing
approval, as well as over the
counter sales opportunities in
the near term.
Investor Presentation
4View entire presentation